Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

WCLC 2020: Updated Overall Survival With Atezolizumab in NSCLC From IMpower110

By: Vanessa A. Carter, BS
Posted: Tuesday, February 16, 2021

Roy S. Herbst, MD, PhD, of Yale Cancer Center, New Haven, Connecticut, and colleagues conducted the IMpower110 study to evaluate the efficacy of first-line atezolizumab in PD-L1–selected squamous or nonsquamous non–small cell lung cancer (NSCLC). The investigators reported an improvement in overall survival in patients who had TC3 or IC3–wild-type disease, and their results were presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer in Singapore (WCLC), held in virtual format in January 2021 (Abstract FP13.03).

Selected patients had stage IV NSCLC (PD-L1 TC1/2/3 or IC1/2/3 disease; they received no previous chemotherapy had an Eastern Cooperative Oncology Group performance status of 0 to 1. Participants were randomly assigned 1:1 to either Arm A or B. Individuals in arm A received 1,200 mg of intravenous atezolizumab, and patients in arm B received platinum-based chemotherapy for four to six 21-day cycles.

Additionally, patients in arm B with nonsquamous disease were administered 75 mg/m2 of cisplatin or carboplatin AUC 6, plus 500 mg/m2 of intravenous pemetrexed; in contrast, patients with squamous disease received 75 mg/m2 of cisplatin plus 1,250 mg/m2 of gemcitabine or carboplatin AUC 5 plus 1,000 mg/m2 of intravenous gemcitabine.

In arm A, the overall survival in patients with TC2/3 or IC2/3–wild-type disease seemed to be improved, although the improvement was not statistically significant. Although overall survival could not be tested formally for individuals with TC1/2/3 or IC1/2/3–wild-type disease, exploratory overall survival analysis showed clinically relevant improvement in those with TC3 or IC3–wild-type disease.

Treatment-related adverse events affected 62.9% of participants in arm A and 85.2% in arm B. Grade 3 to 4 treatment-related adverse events occurred in 14.3% and 44.9% of patients, respectively.

Disclosure: For full disclosures of the study authors, visit wclc.iaslc.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.